PAM
NTLA icon

Panagora Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Panagora Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-99,301
Closed -$893K – 1243
2025
Q4 		$893K Sell
99,301
-99,359
-50% -$1.37M ﹤0.01% 750
2025
Q3 		$3.43M Buy
+198,660
New +$2.45M 0.01% 420
2024
Q3 		– Sell
-17,748
Closed -$397K – 1247
2024
Q2 		$397K Buy
+17,748
New +$423K ﹤0.01% 975
2022
Q1 		– Sell
-1,739
Closed -$206K – 1569
2021
Q4 		$206K Sell
1,739
-44
-2% -$5.51K ﹤0.01% 1482
2021
Q3 		$239K Hold
1,783
– – ﹤0.01% 1593
2021
Q2 		$289K Sell
1,783
-98
-5% -$7.63K ﹤0.01% 1537
2021
Q1 		$151K Buy
1,881
+1,693
+901% +$114K ﹤0.01% 1796
2020
Q4 		$10K Buy
+188
New +$6.83K ﹤0.01% 2298
2016
Q4 		– Sell
-31,250
Closed -$532K – 2400
2016
Q3 		$532K Buy
+31,250
New +$605K ﹤0.01% 1429

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Panagora Asset Management's NTLA Position: Q1 2026 in Review

Panagora Asset Management sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 99,301 shares — an estimated $893K sold.

Panagora Asset Management first reported a position in NTLA in Q3 2016 and held it in 9 quarters. The position peaked at $3.43M in Q3 2025. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Panagora Asset Management reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Panagora Asset Management sold 99,301 Intellia Therapeutics shares in Q1 2026, an estimated $893K.
  • Panagora Asset Management first reported a position in Intellia Therapeutics in Q3 2016 and held it in 9 quarters.
  • Panagora Asset Management's Intellia Therapeutics position peaked at $3.43M in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Panagora Asset Management's 13F filing for Q1 2026, filed 14 May 2026.